WeTrials

A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer

What is this study?

This study is testing a combination of two medications, niraparib and dostarlimab, to see how well they work against advanced cancers that struggle to repair their own DNA. Researchers hope this combination can help target and shrink specific types of tumors that have spread.

Who can participate?

You might be able to join if you are 18 or older, can handle daily activities well, and have an advanced cancer with specific gene changes related to DNA repair, such as BRCA mutations. However, certain cancers like prostate cancer or inherited BRCA-positive breast, ovarian, and pancreatic cancers cannot take part.

What will happen?

Participants will receive a combination of study drugs designed to fight their cancer. Your health and safety will be carefully monitored by the medical team throughout the study process.

Where and when?

The study currently takes place in Germantown, Tennessee, and its status is unknown, so you may want to contact the study coordinators directly to check if they are actively enrolling.

Key Points
  • 1Tests a combination of two cancer-fighting medications
  • 2For adults with advanced solid tumors having specific DNA repair gene mutations
  • 3Takes place in Germantown, Tennessee, with active status currently needing verification

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Homologous Recombination Deficient Solid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.